Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03003676 |
| Title | A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Targovax Oy |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | NOR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Maryland Comprehensive Cancer Center | Baltimore | Maryland | United States | Details | ||
| Memorial Sloan Kettering Cancer Center | New York | New York | United States | Details | ||
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | United States | Details | ||
| Oslo University Hospital - The Norwegian Radium Hospital | Oslo | Norway | Details |